# Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

> **NCT03379428** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **US Oncology Research** · enrollment: 34 (actual)

## Conditions studied

- Breast Neoplasms
- Malignant Neoplasm of Breast

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Ibrutinib 560 mg
- **DRUG:** Ibrutinib 840 mg
- **DRUG:** Ibrutinib 420 mg

## Key facts

- **NCT ID:** NCT03379428
- **Lead sponsor:** US Oncology Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-29
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03379428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03379428, "Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03379428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*